Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$64.81T
24h Vol:
$9.25B
Dominance:
MSFT:4.76%
Stocklytics Platform
Asset logo  JAGX
Jaguar Health
JAGX
62 / 100
Penny Stock
$0.26arrow_drop_down6.96%-$0.02

Performance History

Stocklytics logo
Key Stats
Open$0.27
Prev. Close$0.28
EPS-1.79
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap83898136.00
PE Ratio-
LOWHIGH
Day Range0.26
0.27
52 Week Range0.05
0.75
Ratios
P/B Ratio5.15
Revenue$9.76M
Operating M. %-349.43%
Earnings$0.00
Earnings Growth %15.84%
EBITDA Margin %-310.21%
ROE %-353.98%
EPS-1.79

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$769.70
24H (%)arrow_drop_down0.18%
24H ($)-$1.41
MARKET CAP$722.30B
PRICE$522.46
24H (%)arrow_drop_up0.23%
24H ($)$1.19
MARKET CAP$471.98B
PRICE$153.98
24H (%)arrow_drop_down0.18%
24H ($)-$0.29
MARKET CAP$360.78B
PRICE$130.78
24H (%)arrow_drop_down0.06%
24H ($)-$0.09
MARKET CAP$329.41B

About Jaguar Health (JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Lisa A. Conte
Headquarters
San Francisco
Employees
60
Exchange
NASDAQ
add Jaguar Health  to watchlist

Keep an eye on Jaguar Health

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Jaguar Health 's (JAGX) price per share?

The current price per share for Jaguar Health (JAGX) is $0.27. The stock has seen a price change of -$0.02 recently, indicating a -6.97% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Jaguar Health (JAGX)?

For Jaguar Health (JAGX), the 52-week high is $0.75, which is 180.9% from the current price. The 52-week low is $0.05, the current price is 423.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Jaguar Health (JAGX) a growth stock?

Jaguar Health (JAGX) has shown an average price growth of 0.41% over the past three years. It has received a score of -6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Jaguar Health as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Jaguar Health (JAGX) stock price performance year to date (YTD)?

As of the latest data, Jaguar Health (JAGX) has a year-to-date price change of 76.59%. Over the past month, the stock has experienced a price change of 49.75%. Over the last three months, the change has been 241.87%. Over the past six months, the figure is -26.85%. Looking at a longer horizon, the five-year price change stands at -99.99%.

help
Is Jaguar Health (JAGX) a profitable company?

Jaguar Health (JAGX) has a net income of -$41.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 54.67% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -349.43% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.76M, although specific revenue growth data is currently not available. The gross profit is $5.34M. Operating income is noted at -$33.92M. Furthermore, the EBITDA is -$31.91M.

help
What is the market capitalization of Jaguar Health (JAGX)?

Jaguar Health (JAGX) has a market capitalization of $83.9M. The average daily trading volume is 37.69M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level